Jeppe Zacho1, Anne Tybjaerg-Hansen, Børge G Nordestgaard. 1. Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Abstract
OBJECTIVE: To examine the robustness of the association between C-reactive protein (CRP) levels and increased risk of venous thromboembolism (VTE) and to examine whether genetically elevated CRP levels cause VTE. METHODS AND RESULTS: In the prospective Copenhagen City Heart Study, we observed 10 388 participants for longer than 16 years, of whom 484 developed a VTE. In the cross-sectional Copenhagen General Population Study, we studied 36 616 participants, of whom 903 previously had a VTE. Levels of CRP greater than 3 mg/L versus less than 1 mg/L were associated with a 2.3- and 2.4-fold increased risk of VTE in the Copenhagen City Heart Study and the Copenhagen General Population Study, respectively. CRP levels in tertiles, quintiles, and octiles associated with a stepwise increase in VTE risk. CRP genotypes associated with an increase in plasma CRP levels up to 59% but did not associate consistently with risk of VTE in either study. The causal odds ratio for VTE for a doubling in genetically elevated CRP on instrumental variable analyses was lower than the odds ratio for VTE observed for a doubling in plasma CRP on logistic regression ([odds ratio and 95% CI] 0.80 [0.56 to 1.12] versus 1.17 [1.08 to 1.27]; P=0.04). CONCLUSIONS: We observed 47,000 participants from the general population, of whom 1387 developed VTE. Although elevated CRP levels robustly associated with increased risk of VTE, this may not necessarily be a causal association because genetically elevated CRP did not associate with VTE risk.
OBJECTIVE: To examine the robustness of the association between C-reactive protein (CRP) levels and increased risk of venous thromboembolism (VTE) and to examine whether genetically elevated CRP levels cause VTE. METHODS AND RESULTS: In the prospective Copenhagen City Heart Study, we observed 10 388 participants for longer than 16 years, of whom 484 developed a VTE. In the cross-sectional Copenhagen General Population Study, we studied 36 616 participants, of whom 903 previously had a VTE. Levels of CRP greater than 3 mg/L versus less than 1 mg/L were associated with a 2.3- and 2.4-fold increased risk of VTE in the Copenhagen City Heart Study and the Copenhagen General Population Study, respectively. CRP levels in tertiles, quintiles, and octiles associated with a stepwise increase in VTE risk. CRP genotypes associated with an increase in plasma CRP levels up to 59% but did not associate consistently with risk of VTE in either study. The causal odds ratio for VTE for a doubling in genetically elevated CRP on instrumental variable analyses was lower than the odds ratio for VTE observed for a doubling in plasma CRP on logistic regression ([odds ratio and 95% CI] 0.80 [0.56 to 1.12] versus 1.17 [1.08 to 1.27]; P=0.04). CONCLUSIONS: We observed 47,000 participants from the general population, of whom 1387 developed VTE. Although elevated CRP levels robustly associated with increased risk of VTE, this may not necessarily be a causal association because genetically elevated CRP did not associate with VTE risk.
Authors: Antonio P Arenas de Larriva; Alvaro Alonso; Faye L Norby; Nicholas S Roetker; Aaron R Folsom Journal: J Thromb Haemost Date: 2019-03-18 Impact factor: 5.824
Authors: N C Olson; M Cushman; P L Lutsey; L A McClure; S Judd; R P Tracy; A R Folsom; N A Zakai Journal: J Thromb Haemost Date: 2014-10-31 Impact factor: 5.824
Authors: Erin M Hald; Sigrid K Brækkan; Ellisiv B Mathiesen; Inger Njølstad; Tom Wilsgaard; Jan Brox; John-Bjarne Hansen Journal: Haematologica Date: 2011-04-20 Impact factor: 9.941
Authors: Lars D Horvei; Sigrid K Brækkan; Ellisiv B Mathiesen; Inger Njølstad; Tom Wilsgaard; John-Bjarne Hansen Journal: Eur J Epidemiol Date: 2014-09-12 Impact factor: 8.082